Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models

BACKGROUND: Trastuzumab is currently approved for the clinical treatment of breast and gastric cancer patients with HER-2 positive tumors, but not yet for the treatment of esophageal carcinoma patients, whose tumors typically show 5 ~ 35% HER-2 gene amplification and 0 ~ 56% HER-2 protein expression...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Xianhua, Zhang, Jingchuan, Zhen, Ruheng, Lv, Jing, Zheng, Li, Su, Xinying, Zhu, Guanshan, Gavine, Paul R, Xu, Songtao, Lu, Shaohua, Hou, Jun, Liu, Yalan, Xu, Chen, Tan, Yunshan, Xie, Liang, Yin, Xiaolu, He, Deming, Ji, Qunsheng, Hou, Yingyong, Ge, Di
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3485623/
https://www.ncbi.nlm.nih.gov/pubmed/22935382
http://dx.doi.org/10.1186/1479-5876-10-180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3485623/
https://www.ncbi.nlm.nih.gov/pubmed/22935382
http://dx.doi.org/10.1186/1479-5876-10-180

Ejemplares similares